Cargando…

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Soomin, Hwang, Soo Hyun, Han, Joungho, Choi, Yoon-La, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju, Park, Woong-Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pathologists and the Korean Society for Cytopathology 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963973/ https://www.ncbi.nlm.nih.gov/pubmed/27160687 http://dx.doi.org/10.4132/jptm.2016.04.19

Ejemplares similares

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
por: Hwang, Soohyun, et al.
Publicado: (2021)

Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria
por: Hwang, Soohyun, et al.
Publicado: (2017)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
por: Park, Hyung Kyu, et al.
Publicado: (2017)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Pleural Mesothelioma: An Institutional Experience of 66 Cases
por: Ahn, Soomin, et al.
Publicado: (2014)

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
por: Park, Sehhoon, et al.
Publicado: (2022)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Clinicopathological Analysis of 21 Thymic Neuroendocrine Tumors
por: Ahn, Soomin, et al.
Publicado: (2012)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
por: Lee, Ji Hyun, et al.
Publicado: (2016)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
por: Kim, Hongsik, et al.
Publicado: (2022)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
por: Park, Song Ee, et al.
Publicado: (2019)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Pulmonary Arteriovenous Fistula: Clinical and Histologic Spectrum of Four Cases
por: Ahn, Soomin, et al.
Publicado: (2016)

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
por: Park, Sehhoon, et al.
Publicado: (2019)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2016)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system
por: Jung, Hyun Ae, et al.
Publicado: (2021)

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy
por: Lee, Soohyeon, et al.
Publicado: (2011)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
por: Kim, Gahyun, et al.
Publicado: (2020)

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
por: Ahn, Myung-Ju, et al.
Publicado: (2012)

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
por: Chi, Sang Ah, et al.
Publicado: (2023)

A Rare Case of Pulmonary Arteriovenous Hemangioma Presenting as a Peribronchial Mass
por: Ahn, Soomin, et al.
Publicado: (2016)

A Rare Case of Tumor-to-Tumor Metastasis of Thyroid Papillary Carcinoma within a Pulmonary Adenocarcinoma
por: Lee, Taebum, et al.
Publicado: (2015)

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
por: Kim, Nayoung, et al.
Publicado: (2020)

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6kv1ohiq5l2sholeqhkl17arfu